FREMONT, Calif., Feb. 9, 2012 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTCBB: WGBS), an emerging genomic analysis company, today announced that the company will deliver its corporate presentation at the 14th Annual BIO CEO & Investor Conference, February 13 and 14, 2012 at the Waldorf Astoria, New York, NY.
WaferGen's presentation will begin at 2:00 p.m. Eastern Time, Monday, February 13, 2012. The presentation will be Webcast live and may be accessed at www.wafergen.com. It will be available for 90 days.
About WaferGen and the SmartChip Real-Time PCR System
WaferGen Biosystems, Inc., an emerging genomic analysis company in the early stage of commercialization, develops products to address key unmet needs in large and growing markets in disease research and personalized medicine. The company offers the transformative SmartChip Real-Time PCR Systema next-generation Real-Time PCR system for profiling and validation of gene expression patterns (biomarkers) on a single platform. The company believes that the capability of the SmartChip platform to accurately make qualitative and quantitative genome measurements is an integral tool in enabling researchers to verify the results coming from next-generation sequencers. Once verified, this content creates a larger, longer-term opportunity for WaferGen as it significantly increases the ability of researchers to validate high value genomic targets for their ultimate use in developing new/improved drugs and diagnostic tests.
The company also offers an innovative fee-based service for gene-expression profiling using the SmartChip System. For additional information, please see http://www.wafergen.com
Don Huffman, CFO
Media: Joyce Strand
Investors: Jeff Ransom, ProActive
SOURCE WaferGen Biosystems, Inc.